Clinical Inquiries

How effective are opioids for chronic low back pain?

Author and Disclosure Information

 

References

A small RCT (36 patients who had suffered low back pain for more than 6 months) randomized patients to one of 3 treatment groups for 16 weeks: oxycodone as much as 20 mg/d (13 patients); naproxen as much as 1 g/d (12 patients); or oxycodone and sustained-release morphine (titrated up to 200 mg morphine equivalent/d (11 patients).3 After 16 weeks, patients receiving oxycodone or naproxen were treated with oxycodone and sustained-release morphine for another 16 weeks, as were patients already receiving this therapy. Pain was assessed on a 0 (none) to 100 (worst possible pain) scale.

Both opioid groups had significantly less pain on average (59.8 for oxycodone, 54.9 for titrated morphine) than the naproxen group (65.5; F=16.07; P<.001) but no significant difference in activity level. However, an independent analysis of the naproxen group and titrated morphine group found no significant difference in either pain relief (SMD= -0.58; 95% CI, -1.42 to 0.26) or disability (SMD= -0.06; 95% CI, -0.88 to 0.76) between the 2 groups.4

How does long-term opioid use affect pain and function?

Two prospective cohort studies have evaluated long-term opioid use. The first (715 patients) used a Roland-Morris Disability Questionnaire (RMDQ) to assess disability at 6 months in patients taking opioids compared with patients not taking opioids.5 Patients using opioids showed an increase in RMDQ score of 1.18 units (95% CI, 0.17-2.19) on a 0 to 24 scale, with 24 representing greatest disability.

Short-term treatment with opioids provides modest relief of chronic low back pain, but only minimal improvement in function compared with placebo.

The second study evaluated pain and function in 1843 adults with acute back injuries taking opioids for a year.6 Pain, rated on a 0 to 10 scale, decreased from 7.7 at baseline to 6.8 at one year (no P value). At the end of the first quarter, the RMDQ score decreased from 18.8 at baseline (the end of the first quarter) to 17.5 at one year (no P value). Clinically meaningful improvement in pain and function (30% or more) occurred in 26% (95% CI, 18%-36%) and 16% (95% CI, 10%-25%) of patients, respectively.

RECOMMENDATIONS

The 2007 clinical practice guideline on low back pain from The American College of Physicians and American Pain Society recommends opioids, including tramadol, for patients with severe back pain who don’t get adequate relief from acetaminophen or NSAIDs.7

The 2009 National Institute for Health and Care Excellence (NICE) guidelines for early management of persistent, nonspecific low back pain recommend considering strong opioids (buprenorphine, fentanyl, and oxycodone) for short-term use in severe pain and referral to a specialist for patients requiring prolonged use of strong opioids.8

The 2013 British Pain Society guidelines for low back and radicular pain recommend tight restrictions on the use of strong opioids. They also recommend giving the lowest possible dose of opioids for the shortest time possible.9

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

VIDEO: Primary care is pain care’s front line
MDedge Family Medicine
Nocturnal back pain suggests systemic disorder
MDedge Family Medicine
New shingles vaccine delivers whopping efficacy
MDedge Family Medicine
Federal plan emphasizes heroin/opioid treatment over incarceration
MDedge Family Medicine
Sexual abuse history may promote migraine transformation
MDedge Family Medicine
Zeroing in on the cause of your patient's facial pain
MDedge Family Medicine
Fibromyalgia • anxiety/depression • urinary retention • Dx?
MDedge Family Medicine
Tailor chronic pain interventions to your patient’s clinical profile
MDedge Family Medicine
Hydroxyurea boosts O2 saturations in children with sickle cell disease
MDedge Family Medicine
Nipple Raynaud’s can freeze out breastfeeding desire
MDedge Family Medicine